ARS Pharma narrows commercial focus for neffy, sees CSU data in Q1 2027

ARS Pharmaceuticals said on August 13, 2026 that it is shifting its focus from broad consumer-directed marketing toward targeted engagement with high-volume prescribers, a strategy the company said has already grown its field-targeted market share.¹ The company also completed the expansion of its field sales organization, which will concentrate on the highest-value prescribers, representing 44% of the total U.S. market opportunity.¹ Meg Smith was named Chief Commercial Officer effective August 17, 2026, having most recently led the commercial organization at Dynavax Technologies that launched HEPLISAV-B.¹

On the pipeline, ARS Pharma's Phase 2b trial in chronic spontaneous urticaria (CSU), called ARS-2, is underway, assessing rapid relief of acute flares with intranasal epinephrine compared to placebo, with enrollment completed in the interim patient population.¹ The design calls for each enrolled patient to experience and log three separate flare episodes, each treated with either placebo or a varying dose of intranasal epinephrine.¹ Because of the time needed to complete those episodes, the company expects interim Phase 2b data in the first quarter of 2027.¹ ARS Pharma noted there are currently no FDA-approved, on-demand products to manage acute CSU flares.¹

On finances, second-quarter net product revenue for neffy was $26.2 million, bringing 2026 year-to-date net product revenue to $43.7 million, with total U.S. epinephrine market share of 5%, double the 2.5% share in the same period of 2025, and 8% share among field-targeted accounts.¹ The company guided second-half 2026 cash-based SG&A and R&D expenses to $100 million to $110 million, reflecting a more than 40% cut in cash-based SG&A spending compared with the first half of 2026, a trend it expects to continue through 2027.¹ ARS Pharma said it anticipates reaching cash flow breakeven by the end of 2027 based on this revised expense plan.¹ As of June 30, 2026, the company reported $143.8 million in cash, cash equivalents, and short-term investments.¹